34 Results for "

KY

" in MedChemExpress (MCE) Product Catalog:
Products (34)

34 Results for "KY" in MCE Product Catalog:

168
168 Publications Verification
Cat. No.: HY-10197
CAS No.: 19545-26-7
Purity:  99.85%
Synonyms: SL-2052; KY-12420
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively .
5
5 Cited Publications
Cat. No.: HY-13815
CAS No.: 1118807-13-8
Purity:  99.23%
Target:  

Wnt

Research Areas:  

Cardiovascular Disease

KY02111 is a canonical WNT signaling (β-catenin) inhibitor which promotes differentiation of hPSCs to cardiomyocytes. KY02111 can be used for the research of human cardiomyocyte regeneration .
4
4 Cited Publications
Cat. No.: HY-131447
CAS No.: 2226664-93-1
Purity:  ≥98.0%
Synonyms: A3051
Target:  

GSK-3 Wnt β-catenin

Research Areas:  

Metabolic Disease

KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC50s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be used for the research of high fat diet (HFD) induced metabolic diseases .
3
3 Cited Publications
Cat. No.: HY-102028
CAS No.: 292168-79-7
Purity:  ≥98.0%
Target:  

Wnt β-catenin

Research Areas:  

Cancer

KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway, with an IC50 of 2.1 μM in HEK293 reporter cells .
2
2 Cited Publications
Cat. No.: HY-120327
CAS No.: 1621673-53-7
Purity:  98.42%
Target:  

Phosphatase

KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury .
1
1 Cited Publications
Cat. No.: HY-124745
CAS No.: 1228280-29-2
Purity:  99.88%
Target:  

MAP4K Wnt Apoptosis

Research Areas:  

Cancer

KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity .
1
1 Cited Publications
Cat. No.: HY-P99434
CAS No.: 2378692-15-8
Synonyms: KY1005; SAR445229

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis .
1
1 Cited Publications
Cat. No.: HY-U00148
CAS No.: 110816-78-9
Synonyms: N556
Target:  

Drug Derivative

Research Areas:  

Inflammation/Immunology

KY-556 is a promising and orally-active pro-agent of disodium cromoglycate (DSCG) against allergic diseases.
Cat. No.: HY-156418
CAS No.: 2787598-01-8
KY386 is a DHX33 helicase inhibitor with an IC50 of 0.019 μM. KY386 inhibits the cell viability of various cancer cells. KY386 induces ferroptosis in cancer cells, and induces apoptosis in some cancer cell lines. KY386 increases the intracellular levels of ROS, LPO and Fe 2+, and decreases the level of GSH in cancer cells . KY386 inhibits the growth of gastric cancer and colon cancer xenografts in nude mice. KY386 is applicable to the related research on liver cancer, lung cancer, pancreatic cancer, colorectal cancer, gastric cancer, breast cancer, leukemia, renal cancer, prostate cancer, esophageal cancer, cervical cancer, brain cancer (glioblastoma) and melanoma .
Cat. No.: HY-147084
Purity:  98.20%
Target:  

ADC Linkers

Research Areas:  

Metabolic Disease Cancer

KY371 is a click chemistry reagent containing an alkyne group. KY371 is a broad-range glycosidase inhibitor. KY371 can combine with proteomic analysis of targeted protein to study glycosidases .
Cat. No.: HY-124156A
CAS No.: 2989396-34-9
Purity:  99.24%
Target:  

Wnt

Research Areas:  

Metabolic Disease

KY-02327 acetate, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 acetate shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation .
Cat. No.: HY-P99431
CAS No.: 2489390-15-8
Synonyms: Alomfilimab; SAR 445256

Target:  

CD28

Research Areas:  

Inflammation/Immunology Cancer

KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 + TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
Cat. No.: HY-174461
Target:  

PROTACs PI3K

Research Areas:  

Cancer

PROTAC PI3Kα degrader-1 is a PI3Kα PROTAC degrader (DC50 = 0.08 μM), demonstrating good selectivity for PI3Kα degradation over PI3Kβ, PI3Kγ, and PI3Kδ. PROTAC PI3Kα degrader-1 effectively degrades PI3Kα in a time- and concentration-dependent, over PI3Kβ, PI3Ky and PI3Kδ, and potently inhibited the phosphorylation of AKT at the Ser473site. PROTAC PI3Kα degrader-1 shows significant in vivo anticancer efficacy in HGC-27 and DOHH2 xenograft models .
Cat. No.: HY-124156
CAS No.: 2093407-25-9
Target:  

Wnt

Research Areas:  

Metabolic Disease

KY-02327, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation .
Cat. No.: HY-178227
CAS No.: 2319609-67-9
KY19334 is a CXXC5-DVL inhibitor. KY19334 can activate the Wnt/β-catenin pathway by inhibiting CXXC5-Dvl interaction. KY19334 can inhibit cancer cells proliferation, migration, invasion and transformation by inhibiting CDK1. KY19334 can accelerate wound healing and exert regenerative effects. KY19334 can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as cutaneous squamous cell carcinoma and diabetes .
Cat. No.: HY-124764
CAS No.: 468056-29-3
Target:  

PAK

Research Areas:  

Cancer

KY-04031 is a potent PAK4 inhibitor with IC50 of 0.79 μM. KY-04031 binds to the ATP-binding pocket of PAK4. KY-04031 blocks tumor cell growth and invasion .
Cat. No.: HY-113680
CAS No.: 1029721-36-5
Target:  

Apoptosis Ras β-catenin Wnt

Research Areas:  

Cancer

KY1022 is a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway. KY1022 can inhibit cellular EMT, metastasis and apoptosis. KY1022 can be used for the research of metastatic colorectal cancer .
Cat. No.: HY-117218
CAS No.: 1223284-75-0
Target:  

PAK

Research Areas:  

Cancer

KY-04045 is a PAK4 specific inhibitor (IC50=8.7 μM) that can be used for the development of anticancer drugs targeting PAK4 .
Cat. No.: HY-10197R
CAS No.: 19545-26-7
Synonyms: SL-2052 (Standard); KY-12420 (Standard)
Wortmannin (Standard) is the analytical standard of Wortmannin. This product is intended for research and analytical applications. Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively .
Cat. No.: HY-113773
CAS No.: 90278-40-3
Target:  

Bacterial

Research Areas:  

Infection

KY-9 is an antibacterial active compound .